498 related articles for article (PubMed ID: 27830540)
21. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
22. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
23. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
24. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
25. [EZH2 is therapeutic target for personalized treatment in multiple myeloma].
Herviou L; Cavalli G; Moreaux J
Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976
[TBL] [Abstract][Full Text] [Related]
26. EZH2 inhibitors: a patent review (2014-2016).
Stazi G; Zwergel C; Mai A; Valente S
Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
[TBL] [Abstract][Full Text] [Related]
27. Deregulated Polycomb functions in myeloproliferative neoplasms.
Sashida G; Oshima M; Iwama A
Int J Hematol; 2019 Aug; 110(2):170-178. PubMed ID: 30706327
[TBL] [Abstract][Full Text] [Related]
28. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma.
Sanna L; Marchesi I; Melone MAB; Bagella L
J Cell Physiol; 2018 Sep; 233(9):6508-6517. PubMed ID: 29574790
[TBL] [Abstract][Full Text] [Related]
29. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
[TBL] [Abstract][Full Text] [Related]
30. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
Zhang Y; Tong T
Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
[TBL] [Abstract][Full Text] [Related]
31. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
32. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
33. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
[TBL] [Abstract][Full Text] [Related]
34. MUC1-C activates EZH2 expression and function in human cancer cells.
Rajabi H; Hiraki M; Tagde A; Alam M; Bouillez A; Christensen CL; Samur M; Wong KK; Kufe D
Sci Rep; 2017 Aug; 7(1):7481. PubMed ID: 28785086
[TBL] [Abstract][Full Text] [Related]
35. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.
Deb G; Thakur VS; Gupta S
Epigenetics; 2013 May; 8(5):464-76. PubMed ID: 23644490
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
37. [Research Progress of Expression and Clinical Significant of EZH2 in Hematological Malignancies--Review].
Hu JY; Ji YR; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):2097-2012. PubMed ID: 33283749
[TBL] [Abstract][Full Text] [Related]
38. Targeting EZH2 in cancer therapy.
Yamagishi M; Uchimaru K
Curr Opin Oncol; 2017 Sep; 29(5):375-381. PubMed ID: 28665819
[TBL] [Abstract][Full Text] [Related]
39. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
Alzrigat M; Jernberg-Wiklund H; Licht JD
Epigenomes; 2018 Sep; 2(3):. PubMed ID: 30761216
[TBL] [Abstract][Full Text] [Related]
40. EZH2: not EZHY (easy) to deal.
Deb G; Singh AK; Gupta S
Mol Cancer Res; 2014 May; 12(5):639-53. PubMed ID: 24526064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
